Skip to main content

Advertisement

SpringerLink
Log in

Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia

  • Original Article
  • Published:
Tumor Biology

Abstract

There are a paucity and contradicted data about the impact of concurrent heredity of polymorphic genes and risk of chronic myeloid leukemia (CML). In the present study, the concurrent effects of three polymorphisms affecting the integrity of DNA consist of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp on development of chronic myeloid leukemia were studied. Furthermore, the role of these polymorphisms in clinical and laboratory outcomes of patients was evaluated. In this case–control study, 70 CML patients and 140 healthy individuals were enrolled in the study. The clinical features of patients such as phase of disease and response to treatment and laboratory data before and after treatment with imatinib mesylate were collected. ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp single nucleotide polymorphisms were evaluated by restriction fragment length polymorphism–polymerase chain reaction. The T allele of ABCB1 C3435T, T allele of XRCC1 Arg194Trp, and C allele of ABCG2 C421A polymorphisms were significantly higher in patients than controls. TT genotype of ABCB1 and TT genotype of XRCC1 were associated with higher risk of chronic myeloid leukemia development. CC421 ABCG2/TT3435 ABCB1 and CC421 ABCG2/TT27157 XRCC1 were also correlated with a higher risk of CML. Patients with C allele of ABCB1 had poor cytogenetic response, and correlation of CC421 ABCG2/TT3435 ABCB1 diplotype with accelerated phase of CML was significant. Patients with CC421 ABCG2/TT3435 ABCB1 and CC421 ABCG2/TT27157 XRCC1 diplotypes might be at higher risk to rapid and severe development of CML and have weaker response to treatments with imatinib.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Geary CG. The story of chronic myeloid leukaemia. Br J Haematol. 2000;110(1):2–11.

    Article  CAS  PubMed  Google Scholar 

  2. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol. 2012;87(11):1037–45.

    Article  CAS  PubMed  Google Scholar 

  3. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nature reviews. 2007;7(6):441–53.

    CAS  PubMed  Google Scholar 

  4. Taspinar M, Aydos SE, Comez O, Elhan AH, Karabulut HG, Sunguroglu A. CYP1A1, GST gene polymorphisms and risk of chronic myeloid leukemia. Swiss Med Wkly. 2008;138(1–2):12–7.

    CAS  PubMed  Google Scholar 

  5. Belitsky GA, Yakubovskaya MG. Genetic polymorphism and variability of chemical carcinogenesis. Biochemistry (Mosc). 2008;73(5):543–54.

    Article  CAS  Google Scholar 

  6. Lee JS, Ward WO, Liu J, Ren H, Vallanat B, Delker D, et al. Hepatic xenobiotic metabolizing enzyme and transporter gene expression through the life stages of the mouse. PLoS One. 2011;6(9):e24381.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ueda K, Pastan I, Gottesman MM. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem. 1987;262(36):17432–6.

    CAS  PubMed  Google Scholar 

  8. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001;61(8):3458–64.

    CAS  PubMed  Google Scholar 

  9. Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, Vogel U. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009;9:407.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86(2):197–203.

    Article  CAS  PubMed  Google Scholar 

  11. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, Figg WD. Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010;44(2):152–67.

    Article  CAS  PubMed  Google Scholar 

  12. Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009;106(25):10338–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lindahl T, Wood RD. Quality control by DNA repair. Science. 1999;286(5446):1897–905.

    Article  CAS  PubMed  Google Scholar 

  14. Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol. 2005;162(10):925–42.

    Article  PubMed  Google Scholar 

  15. Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure–activity relationship analyses. Drug Metab Pharmacokinet. 2004;19(1):1–14.

    Article  CAS  PubMed  Google Scholar 

  16. Mesallamy HO, Rashed WM, Hamdy NM, Hamdy N. High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next? J Cancer Res Clin Oncol. 2014;140(8):1359–65.

    Article  PubMed  Google Scholar 

  17. Xue H, Ni P, Lin B, Xu H, Huang G. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and gastric cancer risk: a HuGE review and meta-analysis. Am J Epidemiol. 2011;173(4):363–75.

    Article  PubMed  Google Scholar 

  18. Maroofi F, Amini S, Roshani D, Ghaderi B, Abdi M. Different frequencies and effects of ABCB1 T3435C polymorphism on clinical and laboratory features of B cell chronic lymphocytic leukemia in Kurdish patients. Tumour Biol. 2015;36(4):2863–8.

    Article  CAS  PubMed  Google Scholar 

  19. Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol. 2004;72(5):314–21.

    Article  CAS  PubMed  Google Scholar 

  20. Elghannam DM, Ibrahim L, Ebrahim MA, Azmy E, Hakem H. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients. Hematology. 2014;19(3):123–8.

    Article  CAS  PubMed  Google Scholar 

  21. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics. 2003;13(1):19–28.

    Article  CAS  PubMed  Google Scholar 

  22. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res. 2004;10(23):7896–902.

    Article  CAS  PubMed  Google Scholar 

  23. Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, Harvey R, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood. 2006;108(2):685–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer metastasis reviews. 2007;26(1):39–57.

    Article  CAS  PubMed  Google Scholar 

  25. Batar B, Guven M, Baris S, Celkan T, Yildiz I. DNA repair gene XPD and XRCC1 polymorphisms and the risk of childhood acute lymphoblastic leukemia. Leukemia Research. 2009;33(6):759–63.

    Article  CAS  PubMed  Google Scholar 

  26. Banescu C, Duicu C, Trifa AP, Dobreanu M. XRCC1 Arg194Trp and Arg399Gln polymorphisms are significantly associated with shorter survival in acute myeloid leukemia. Leukemia & lymphoma. 2014;55(2):365–70.

    Article  CAS  Google Scholar 

  27. D'Andrea AD. Targeting DNA repair pathways in AML. Best Practice & Research. 2010;23(4):469–73.

    Google Scholar 

  28. Kuptsova N, Kopecky KJ, Godwin J, Anderson J, Hoque A, Willman CL, et al. Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood. 2007;109(9):3936–44.

    Article  CAS  PubMed  Google Scholar 

  29. Seedhouse C, Russell N. Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br J Haematol. 2007;137(6):513–29.

    Article  CAS  PubMed  Google Scholar 

  30. Meza-Espinoza JP, Peralta-Leal V, Gutierrez-Angulo M, Macias-Gomez N, Ayala-Madrigal ML, Barros-Nunez P, et al. XRCC1 polymorphisms and haplotypes in Mexican patients with acute lymphoblastic leukemia. Genet Mol Res. 2009;8(4):1451–8.

    Article  CAS  PubMed  Google Scholar 

  31. Duman N, Aktan M, Ozturk S, Palanduz S, Cakiris A, Ustek D, et al. Investigation of Arg399Gln and Arg194Trp polymorphisms of the XRCC1 (x-ray cross-complementing group 1) gene and its correlation to sister chromatid exchange frequency in patients with chronic lymphocytic leukemia. Genetic Testing and Molecular Biomarkers. 2012;16(4):287–91.

    Article  CAS  PubMed  Google Scholar 

  32. Liu J, Song B, Wang Z, Song X, Shi Y, Zheng J, et al. DNA repair gene XRCC1 polymorphisms and non-Hodgkin lymphoma risk in a Chinese population. Cancer Genetics and Cytogenetics. 2009;191(2):67–72.

    Article  CAS  PubMed  Google Scholar 

  33. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164–72.

    Article  CAS  PubMed  Google Scholar 

  35. Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13(7):840–8.

    Article  CAS  PubMed  Google Scholar 

  36. Salanti G, Sanderson S, Higgins JP. Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med. 2005;7(1):13–20.

    Article  PubMed  Google Scholar 

  37. Ioannidis JP. Genetic associations: false or true? Trends in molecular medicine. 2003;9(4):135–8.

    Article  PubMed  Google Scholar 

  38. Ioannidis JP, Ntzani EE, Trikalinos TA. ‘Racial’ differences in genetic effects for complex diseases. Nature genetics. 2004;36(12):1312–8.

    Article  CAS  PubMed  Google Scholar 

  39. Maffioli M, Camos M, Gaya A, Hernandez-Boluda JC, Alvarez-Larran A, Domingo A, et al. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leukemia research. 2011;35(8):1014–9.

    Article  CAS  PubMed  Google Scholar 

  40. Brambila-Tapia AJ. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 2013;65(5):445–54.

    PubMed  Google Scholar 

  41. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002;62(17):4955–62.

    CAS  PubMed  Google Scholar 

  42. Li YH, Wang YH, Li Y, Yang L. MDR1 gene polymorphisms and clinical relevance. Yi chuan xue bao = Acta genetica Sinica. 2006;33(2):93–104.

    PubMed  Google Scholar 

  43. Sailaja K, Surekha D, Nageswara Rao D, Raghunadha Rao D, Vishnupriya S. ABCB1 (MDR1, P-glycoprotein) C3435T gene polymorphism and its possible association with chronic myeloid leukemia prognosis. Curr Trends Biotechnol Pharm. 2008;2:514–22.

    CAS  Google Scholar 

  44. Ali MA, Elsalakawy WA. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate. Medical oncology (Northwood, London, England). 2014;31(11):279.

    Article  Google Scholar 

  45. Au A, Aziz Baba A, Goh AS, Wahid Fadilah SA, Teh A, Rosline H, et al. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2014;68(3):343–9.

    Article  CAS  Google Scholar 

  46. Annamaneni S, Gorre M, Kagita S, Addepalli K, Digumarti RR, Satti V, et al. Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India. Hematology. 2013;18(3):163–8.

    Article  CAS  PubMed  Google Scholar 

  47. Tang L, Xiong T, Jia Q, He Q, Tong X, Peng Y, et al. Study on the association between the Arg194Trp polymorphism in the XRCC1 gene and the risk of hematological malignancies. Tumour Biol. 2014;35(4):3009–16.

    Article  CAS  PubMed  Google Scholar 

  48. Du L, Liu Y, Xue P, Song C, Shen J, He Q, et al. The Arg399Gln polymorphism in the XRCC1 gene is associated with increased risk of hematological malignancies. Tumour Biol. 2015 Jan 27.

  49. Zhang H, Liu H, Jiang G. Genetic polymorphisms of XRCC1 and leukemia risk: a meta-analysis of 19 case–control studies. PLoS One. 2013;8(11):e80687.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Chen P, Zhao L, Zou P, Xu H, Lu A, Zhao P. The contribution of the ABCG2 C421A polymorphism to cancer susceptibility: a meta-analysis of the current literature. BMC Cancer. 2012;12:383.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Hu LL, Wang XX, Chen X, Chang J, Li C, Zhang Y, et al. BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma. Carcinogenesis. 2007;28(8):1740–4.

    Article  CAS  PubMed  Google Scholar 

  52. Korenaga Y, Naito K, Okayama N, Hirata H, Suehiro Y, Hamanaka Y, et al. Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma. International journal of cancer. 2005;117(3):431–4.

    Article  CAS  PubMed  Google Scholar 

  53. Campa D, Butterbach K, Slager SL, Skibola CF, de Sanjose S, Benavente Y, et al. A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk. International journal of cancer. 2011;131(4):803–12.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Muller P, Asher N, Heled M, Cohen SB, Risch A, Rund D. Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. Leukemia research. 2008;32(6):919–29.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to thank all patients and health stuffs who participated in this study. This work has no financial support.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Biology, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran

    Hana Salimizand & Sabrieh Amini

  2. Cellular and Molecular Research Center, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

    Mohammad Abdi

  3. Department of Clinical Biochemistry, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

    Mohammad Abdi

  4. Department of Internal Medicine, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

    Bayazid Ghaderi

  5. Liver and Digestive Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran

    Bayazid Ghaderi

  6. Department of Epidemiology and Biostatistics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

    Namam-Ali Azadi

  7. Division of Hematology–Oncology, Tohid Hospital, Geryashan Boulevard, Sanandaj, Iran

    Bayazid Ghaderi

Authors
  1. Hana Salimizand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sabrieh Amini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammad Abdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bayazid Ghaderi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Namam-Ali Azadi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Mohammad Abdi or Bayazid Ghaderi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salimizand, H., Amini, S., Abdi, M. et al. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. Tumor Biol. 37, 791–798 (2016). https://doi.org/10.1007/s13277-015-3874-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3874-4

Keywords

Search

Navigation